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Abstract: Despite the existence of many promising anti-cancer therapies, not all breast cancers are equally treatable, due partly to the fact that focus has been primarily on a few select breast cancer biomarkers- notably ERα, PR
and HER2. In cases like triple negative breast cancer (ERα-, PR-, and HER2-), there is a complete lack of available
biomarkers for prognosis and therapeutic purposes. The goal of this review is to determine if other steroid receptors, like ERβ and AR, could play a prognostic and/or therapeutic role. Data from various in vitro, in vivo, and clinical
breast cancer studies were examined to analyze the presence and function of ERβ, PR, and AR in the presence and
absence of ERα. Additionally, we focused on studies that examined how expression of the various steroid receptor
isoforms affects breast cancer progression. Our findings suggest that while we have a solid understanding of how
these receptors work individually, how they interact and behave in the presence and absence of other receptors
requires further research. Furthermore, there is an incomplete understanding of how the various steroid receptor
isoforms interact and impact receptor function and breast cancer progression, partly due to the difficulty in detecting all the various isoforms. More large-scale clinical studies must be made to analyze systematically the expression
of steroid hormone receptors and their respective isoforms in breast cancer patients in order to determine how
these receptors interact with each other and in turn affect cancer progression.
Keywords: Breast cancer, steroid hormone receptors, prognostic markers, estrogen, progesterone, androgen

Introduction
Though both estrogen and progesterone receptors are commonly used as prognostic markers
for breast cancer, current endocrine therapy
primarily targets the estrogen receptor, ERα.
Unfortunately, for about 10-15% of breast cancer patients [1-3]- like those diagnosed with
triple negative breast cancer, defined as breast
tumors lacking the expression of estrogen
receptor alpha (ERα), progesterone receptor
(PR) and human epidermal growth factor receptor type 2 (HER2), ERα-/PR-/HER2- - the established endocrine therapies are ineffective,
highlighting an urgent need for additional therapeutic targets in breast cancer. Therefore, the
goal of the following review is to examine the
role of the steroid hormone receptors- ERα,
ERβ, PR, and androgen receptor (AR)- in the
progression of breast cancer in order to deter-

mine their role and utility as prognostic markers
and therapeutic targets.
Steroid receptors: an overview
The steroid hormone receptor subfamily, which
includes estrogen receptor (ER), progesterone
receptor (PR), androgen receptor (AR), and glucocorticoid receptor (GR), is part of the larger
superfamily of nuclear hormone receptors [4].
The members of this superfamily function as
ligand-gated transcription factors that modulate the expression of genes [5]. While unbound
steroid receptors are typically located in the
cytosol, ligand binding induces receptor dimerization and conformational changes which in
turn exposes the nuclear localization signal,
allowing translocation into the nucleus [6].
Once inside the nucleus, the receptor dimer
recognizes and binds specific DNA sequences
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Estrogen receptor
The estrogen receptor (ER)
was identified in the 1950s
by Dr. Elwood V. Jensen as
reviewed in [14, 15]. Eventually, it was determined that
three forms of ER exist- ERα,
ERβ, and GPR-30 [16-19]. All
three ERs are encoded by
different genes located on
different chromosomes [20].
ERα is encoded by the gene
ESR1 located on chromosome 6; ERβ is encoded by
Figure 1. Comparing the functional domains of nuclear hormone receptors.
gene ESR2 on chromosome
NTD, N-terminal A/B hypervariable domain; DBD, DNA binding domain; H,
14; and GPR-30 is encoded
hinge region; LBD, ligand binding domain. Adapted from [196].
by the GPER gene on chromosome 7. While ERα and
that in turn results in enhancing or silencing the
ERβ are nuclear hormone receptors, GPR-30 is
transcription of specific target genes regulated
not a member of the steroid receptor family but
by the receptor [7, 8].
is instead a G-protein coupled receptor that
has been shown to bind and respond to estroAs depicted in Figure 1, nuclear hormone
gen [21-23]. Therefore, since our interest is in
receptors share common functional domains,
the role of steroid hormone receptors in breast
such as a DNA binding domain (DBD), a ligand
cancer, GPR-30 will not be discussed further in
binding domain (LBD), and two transactivation
this review.
domains (AF-1 and AF-2) [9-12]. DBDs contain
two zinc finger motifs that allow them to recogAlthough ERα and ERβ are both expressed in
nize and bind to specific DNA sequences- often
breast tissue and bind to estrogen with similar
referred to as hormone response elements
affinities [24], studies have shown that only
(HREs)- within the promoter and/or enhancer
ERα is necessary for normal mammary gland
regions to regulate transcription. Different stedevelopment [25, 26] leading researchers to
roid hormone receptors bind to different requestion the function of ERβ in normal breast
sponse elements, thus allowing the receptors
tissue. Multiple studies have also reported that
to regulate subsets of genes that are necessary
ERβ expression actually represses ERα expresto elicit a physiological response. The LBD is
sion and function [27, 28]. In addition to the
involved in the binding of specific hormones,
breast, both nuclear receptors are expressed in
which induces dimerization and nuclear transmany other tissues within the human body,
location [9-12]. The two transactivation domaincluding the endometrium, ovary, testes, cereins, AF-1 and AF-2, are important for modulatbral cortex, myocardium, and thyroid [29-32].
ing transcription of the target genes. AF-2 is
However, their expression patterns do differ in
located within the LBD and is involved in ligandcertain tissues- for example, ERα is the sole
dependent transactivation, while AF-1 is found
estrogen receptor expressed in the hippocamin the N-terminal A/B hypervariable domain
pus, and only ERβ is found in prostate tissue
(NTD) and is responsible for ligand-indepen[32].
dent transcriptional activation and mediates
In addition to full length ERα (as shown in
protein-protein interaction with other transFigure 1), there are 2 truncated splice variants
cription factors [13]. AF-1 is also responsive
of ERα- 46 kDa estrogen receptor (ER46) [33]
to phosphorylation by kinases that are activatand 36 kDa estrogen receptor (ER36) [34, 35].
ed in various signaling pathways, including
Some of the full length ERα (ER66) along with
the epidermal growth factor receptor (EGFR)
ER36 and ER46 [36] associate with the plasma
pathway.
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membrane and are referred to as mERs due to
their ability to translocate to the plasma membrane through palmitoylation and caveolin-1
association, which in turn allows for rapid estrogen receptor signaling. ER46 does not have an
AF-1 transactivation domain, which suggests
that ER46 does not mediate any nuclear functions. ER36 lacks both AF-1 and AF-2 transactivation domains, and part of the ligand binding
domain is replaced by a 27 amino acid
sequence in the C terminus [34]. ER36 has
been shown to mediate estrogen stimulation
via mitogen-activated protein kinase (MAPK)
pathway [35].
As with ERα, ERβ also exists as several isoforms- ERβ1 (Figure 1), ERβ1 “short form”,
ERβ2/cx, ERβ3, ERβ4, and ERβ5 [37-40]. Most
are due to the alternative splicing of exons 7
and 8, although the truncated form of ERβ1 is
due to proteolysis at the N-terminus [41, 42].
Of all the isoforms, only ERβ1 contains the
ligand-binding domain [43]. However, it has
been shown that the formation of heterodimers
between ERβ1 and the other isoforms increases the transcriptional activity of ERβ1 [37].
Progesterone receptor
The expression of PR is primarily regulated by
ERα at the transcriptional level [44, 45]. There
are two known isoforms of PR, PR-A and PR-B.
PR-A is a truncated version of PR-B, lacking
164 amino acids at the N-terminus (Figure 1).
The two proteins are transcribed from two different promoters located within the same gene
on chromosome 11 [46] and can form homo- or
heterodimers. Studies using knockout mice
confirmed the functional importance of both
PR isoforms [47, 48]. Although animals lacking
PR-A did not display significant developmental
effects in the mammary glands or thymus, they
did display severe dysfunctions in their ovaries
and uterus resulting in infertility, suggesting
that its primary function is maintaining normal
ovarian and uterine functions [49-52]. Conversely, PR-B knockout-mice retained normal ovarian, uterine, and thymic functions but exhibited
a significant decrease in mammary ductal morphogenesis [49-51, 53], indicating that PR-B
mediates the proliferative effects of progesterone in the mammary gland.
Structural and functional analyses of each PR
isoform suggest that they have different tran-
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scription activation properties when bound to
progesterone [53, 54]. According to Richer et
al., approximately 27% of PR-regulated genes
are controlled by both PR isoforms. However,
this study also indicated that PR-B alone controls the majority of the PR-regulated genes in
comparison to PR-A alone (69% versus 4%) [55]
which may be in part due to PR-B being intrinsically a stronger transcriptional activator than
PR-A. In fact, PR-A has been reported to function as a transcriptional repressor under certain cellular conditions [56]. Curiously however,
it is PR-A- not PR-B- that is more frequently
over-expressed in breast cancer [57]. Some
studies have even indicated that it is not so
much the expression of either isoform but rather the ratio of the two isoforms that are important in breast cancer development. For example, a higher ratio of PR-A/B has been associated with poorer prognosis and response to
hormone therapy [58].
Androgen receptor
AR is expressed in all tissues, including testis,
prostate, foreskin, cervix, vagina, mammary
glands, bone, brain, sebaceous and sweat
glands of the skin, and breast [59-61]. The
gene that codes for the androgen receptor (AR)
is located on the X chromosome [60, 62]. While
AR is closely related to PR and ER, one distinctive feature of the AR protein is the presence of
glutamine and glycine repeats in the N-terminal
activation domain of the receptor which have
been linked to certain cancers and chronic neurological diseases in humans [60, 63, 64]. In
1994, Wilson and McPhaul discovered two isoforms of AR in human genital skin fibroblasts
that are structurally very similar to PR-A and
PR-B [65]. Their formation is due to two distinct
translation initiation sites which result in the
full-length receptor (110 kDa) and an N-terminally truncated form (87 kDa) known as AR-B
and AR-A, respectively (Figure 1). Since 1994,
several low molecular weight isoforms of AR
have been identified, particularly in prostate
cancer cell lines and tumors (reviewed in [66]).
A few different mechanisms are responsible for
these variants, including premature chain termination during translation, proteolysis by calpains, and alternative splicing [66]. Several isoforms, such as AR-V7 (also known as AR3), lack
the LBD and are thus capable of transcription
activation in the absence of androgen (i.e.
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androgen-independent transcription) [67, 68].
Though originally found in prostate cancer
cases that have become androgen deprivation
therapy (ADT) or castration resistant [67-70],
AR-V7 has likewise been found in a substantial
number of primary breast tumors (~50%) and
most breast cancer cell lines [71]. Another AR
variant, Δ3AR, has been found exclusively in
some breast tumors and breast cancer cell
lines but not in normal breast tissue [72].
Originally discovered in patients suffering from
androgen insensitivity syndrome (AIS), the
Δ3AR isoform lacks the second zinc finger in
the DBD, which potentially could reduce its ability to inhibit cell growth, at least within an ERα+
setting [72, 73].
ERα-positive breast cancer
Prognosis and treatment
In 1896, George Thomas Beatson found that
removing the ovaries from patients with
advanced stages of breast cancer resulted in
significant regression, which later lead to the
speculation of estrogen’s stimulating effect on
breast cancer. Hence, oophorectomy and/or
the use of drugs that target the estrogen receptor have become standard therapies for treating estrogen responsive breast cancer. To date,
much of what we know about the relationship
between ER and breast cancer centers primarily on one particular receptor- ERα. In fact, it is
the presence or absence of ERα that determines whether a patient’s breast cancer can
be classified as either estrogen receptor positive or negative, respectively. ERα-negative
breast cancers may express other hormone
receptors such as PR, AR, and even ERβ, but
they are often non-responsive to estrogen. Of
all the breast cancer subtypes, ERα-positive
breast cancer is the most prevalent, accounting for approximately 75% of breast cancers
diagnosed in women [1].
Studies have shown that patients with ERαpositive breast cancers have a better prognosis
because these tumors tend to be lower grade
and have less aggressive phenotypes. Even
patients with metastatic tumors that expressed
ERα often had significantly better survival outcomes in comparison to patients with ERαnegative tumors [74], and this is most likely due
to the fact that most patients with ERα-positive
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tumors also had an increase likelihood of
responding to the established endocrine therapies [74]. However, not all ER-positive tumors
respond to endocrine therapy, and even those
that are initially responsive eventually become
resistant as the disease progresses.
Drugs that specifically target ERα- estrogen
receptor antagonists- can be used to treat or
manage the disease. ER antagonists specifically compete with estrogen and block it from
binding to the receptor. There are two types of
ER antagonists- 1) selective ER modulators
(SERMs), also referred to as partial antagonists, and 2) pure or complete antagonists, also
referred to as selective ER down-regulators
(SERDs) [75]. Among the most common SERMs
are the anti-estrogens tamoxifen and raloxifene. Tamoxifen is effective in antagonizing
estrogen-dependent cancer cell growth by
binding to ERα and promoting the recruitment
of co-repressors rather than co-activators in
mediating transcriptional repression of ER target genes [11, 76]. An example of a pure antagonist or SERD is ICI 182, 780, also referred to
as faslodex or fulvestrant, which binds to either
ERα or β and promotes receptor degradation
[77-79]. Ultimately, ERα is considered a good
prognostic marker for breast cancer not only
because it is vital in both the development and
progression of the disease but also because its
presence determines whether the cancer will
likely respond to anti-estrogen treatment.
Association with progesterone receptors
Of all the ERα+ mammary tumors, about
50-60% are PR+ [80-82]. Yet while the ER status has been well established as a predictive
factor for breast cancer prognosis and cancer
treatment, less is known about the significance
of PR in the presence of ERα. Studies have
shown that tumors expressing both receptors
tend to be less aggressive and least likely to
metastasize [83, 84]. Others have confirmed
that the presence of both ERα and PR in tumors
often translates to better prognosis [83-86].
Specifically, Dunnwald et al. examined the correlation between PR/ERα expression and mortality risk amongst 155,175 breast cancer
patients and found that patients with ERα+/PR+
tumors had lower mortality rates compared to
women with ERα+/PR-, ERα-/PR+, and ERα-/PR-.
The highest mortality rate was seen in ERα-/PR-
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patients. A similar study carried out by Salmen
et al. determined that patients with ERα-/PRtumors had worse prognoses than patients
with ERα-/PR+ or ERα+/PR+ tumors [87].
Furthermore, tumors that have lost PR expression are often more aggressive and have negative prognoses, signifying that PR is an important indicator of the progression of the disease
[82].
Compared to ERα+/PR+ patients, a smaller percentage of ERα+/PR- breast cancer patients
respond to tamoxifen treatment [85, 88-91],
suggesting that PR plays an important role in
endocrine therapy response. This could account
for the consistent observation that not all ERα+
breast cancer patients respond to endocrine
therapies like tamoxifen. As noted earlier, the
presence of ERα may not always be sufficient
to indicate positive outcome towards endocrine
based-therapeutics. This may be due in part to
the fact that expression of the ERα protein
does not always translate to a functional ERα
signaling pathway. Since PR is one of the target
genes of ERα, it has long been proposed that
the expression of PR may serve as a good indicator of ERα functionality and signaling [92].
Studies have in fact confirmed that the presence PR in ERα+ breast cancer significantly
improves the outcome prediction for adjuvant
endocrine therapy [85, 91, 93-96]. Specifically,
Ferno et al. found that patients with ERα+/PR+
tumors had significant increase in response to
adjuvant tamoxifen therapy compared with
patients with ERα+/PR- tumors [94, 97]. Other
studies have also confirmed that PR status can
be a better indicator of tamoxifen response
than ERα status alone [96, 98]. We speculate
that the presence of ERα without PR expression likely suggests a signaling dysfunction in
the ERα pathway that reduces its ability to transcriptionally regulate its target genes; therefore, it is not surprising that the presence of
both ERα and PR is a better indicator of endocrine therapy responsiveness.
Studies have also demonstrated that PR is
associated with overall survival of cancer
patients [85, 99]. Specifically, patients diagnosed as ERα+/PR+ had less cancer recurrence
in comparison to ERα+/PR- cancer patients
[85]. We acknowledge that this reported
decrease in breast cancer recurrence in ERα+/
PR+ patients contradicted earlier studies [86,
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100], but this may be attributed to the researchers’ use of biochemical assays to measure PR,
which lack the sensitivity of other methods
such as immunohistochemistry, which is the
current practice.
Further complicating the analysis of PR’s role in
breast cancer prognosis and therapeutic
response is the existence of the two PR isoforms mentioned previously- PR-A and PR-B.
The ratio of PR-A to PR-B has been shown to
change during the development of breast cancer [55, 101], and this may alter prognosis and
therapeutic response. Although some breast
cancers may express both isoforms, the ratios
of the two receptors vary, with PR-A showing a
higher expression in most tumors [55, 101].
This ratio of PR-A to B can impact the prognosis
and staging of the disease, with an equal to low
PR-A:PR-B ratio associated with lower tumor
grading (G1 and G2) and a high PR-A:PR-B ratio
associated with undifferentiated, higher grade
tumors (G3) [101]. Recent microarray analysis
also suggests that the PR-A:PR-B ratio is a critical determinant of PR target gene selectivity
and response to hormonal stimuli [102]. This
indicates the importance of evaluating the
interplay between PR-A and PR-B when determining the clinical outcomes and responsiveness to endocrine therapy. However, typical
methods used to determine the presence of PR
in tumors are either ligand binding assays using
tumor extracts or antibody-based assays such
as immunohistochemistry [103-106], and neither of these assays is capable of differentiating between the two PR isoforms. In some
cases, immunohistochemistry may only detect
PR-A and not PR-B in formalin fixed tissue,
suggesting that conformational differences
between the two may interfere with detection
[105]. Ultimately, further analysis of the role of
PR-A and PR-B in breast cancer is needed to
provide a better understanding of PR in prognosis and therapeutic response.
Association with ERβ
ERβ is not commonly used as a prognostic
marker for breast cancer, partially because the
presence and function of ERβ in ERα-positive
tumors are not well understood. As with PR, the
existence of several isoforms of ERβ adds to
the confusion and has resulted in conflicting
data, since the majority of studies that analyze
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the role of ERβ in ERα+ cells do not differentiate
between the various ERβ isoforms. Despite this
complexity, some researchers have had the
foresight to study the specific ERβ isoforms,
and several agree that expression of the ligandbinding isoform ERβ1 in ERα+ cells counteracts
ERα activity, thereby suppressing cell proliferation and enhancing apoptosis [39, 107, 108].
Two other studies carried out by Ogawa et al.
and Peng et al. found that overexpression of
the isoform ERβ2/cx inhibited the transcriptional activity of ERα [38, 109], while this same isoform has been shown to enhance the transcriptional activity of ERβ1 [37]. An in vitro study led
by John Hawse concluded that the tamoxifen
metabolite endoxifen worked best at inhibiting
estrogen-mediated cell proliferation in ERα+
cells if ERβ was also expressed [110]. It was
also determined that endoxifen treatment of
cells led to ERβ accumulation and subsequent
increase in ERα/ERβ heterodimers, providing
further evidence that the observed cancer suppressing activity of ERβ is due in part to a direct
interaction between ERβ and ERα. However, a
clinical study analyzing the effect of a 2-year
tamoxifen treatment on 353 patients with
stage II primary breast tumors found that
patients who were ERα-/ERβ+ had significantly
greater distant disease-free survival compared
with patients who were ERα+/ERβ+, suggesting
a mechanism for ERβ independent of ERα
[111]. Since neither the levels of the tamoxifen
metabolite endoxifen nor the exact ERβ isoforms were determined in these patients, it is
difficult to directly compare this study with that
of Hawse’s. Yet these seemingly differing conclusions do point to a rather complex role for
ERβ in breast cancer, which clearly involves
more than just inactivation of ERα.
Association with androgen receptors
AR expression is most commonly associated
with prostate cancer, and prostate tumor progression is as dependent on AR activity as
breast tumor progression is on ERα activity. In
fact, the treatment of prostate cancers usually
involves hindering AR function via ligand depletion, treatment with AR antagonists, or both
[112]. The role of AR in breast cancer is not
quite as clear. AR is frequently expressed in
ductal carcinoma in situ (DCIS) and invasive
breast carcinoma [113]. In addition, most ERα+
breast cancers also appear to express AR, as
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exemplified by a study carried out by Hu et al.
which found that 88% of 1,164 ER positive
breast cancer cases also expressed AR [114].
Another study by Agrawal et al. analyzed the
importance of using AR as a prognostic marker
in 488 breast cancer patients who underwent
radical mastectomies [115]. Data from this
study suggest that the presence of AR increased
the success of adjuvant therapy and prognosis
in patients. Additionally, they found that 50.7%
of breast cancer patients who were AR negative
had lower 5-year survival rates, indicating poorer prognosis [115]. In yet another study carried
out by Qu and colleagues, 109 breast cancer
patients in Shanghai were retrospectively analyzed between 2003 and 2008 [116]. Of the
109 patients, 52 were diagnosed AR+. Overall,
there were 13 deaths and 15 recurrences but
only two of the deaths and three of the recurrences were from the AR+ group, which again
indicates that AR could be a good marker for
longer overall survival and lower risk of recurrence. Conversely, mammary tumors that do
not express AR have been shown to respond
poorly to hormone therapy [117]. The absence
of AR has also been correlated with higher
levels of Ki-67, a cell proliferation marker associated with cancer progression [118], though
the molecular mechanism behind this finding
has not been elucidated. Furthermore, androgen-activated AR appears to directly bind to the
ERβ promoter and enhance transcription of
ERβ in both ERα-positive and -negative breast
cancer cells [119], suggesting that blocking
AR function may subsequently decrease ERβdependent gene expression.
Although many studies appear to support
the hypothesis that AR helps counteract the
tumorigenic effects of ERα, others- such as one
carried out by Paliouras and Diamandis- report
a synergistic mechanism between the two
receptors, resulting in an increase in breast
cancer progression [120]. Specifically, the ERdependent expression of a group of cancer biomarkers called kallikrein (KLKs) genes was
shown to be enhanced significantly by the binding of androgen to AR. One noteworthy limitation of this study is that it focused on just one
breast cancer cell line (BT474) and therefore
may not be indicative of most breast cancer
cases. Another study by Liao et al. showed that
simultaneous treatment with androgen and
estrogen stimulated mammary gland carcino-
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mas in 100% of the Noble rats tested [121].
The researchers concluded that high levels of
androgen and estrogen together may be an
important risk factor for breast cancer and that
direct binding of androgens to either AR or PR
were involved in this carcinogenic process.
However, although the researchers analyzed
various isoforms of ER and PR, they only concentrated on the two AR isoforms, AR-A and
AR-B, and used only male rats in their study.
Additionally-and perhaps most importantly- the
authors did not sufficiently rule out the possibility that the results were due to aromatization of
androgen to estrogen. A more recent study carried out by Richer and colleagues did determine
that treatment of AR+/ERα+ breast cancer cell
lines with the AR inhibitor enzalutamide- a drug
currently used to treat metastatic prostate cancer- effectively inhibited cell proliferation both
in vitro and in animal models, suggesting that
AR activity may indeed promote cancer progression in the presence of ERα [122]. Yet
again, isoforms of AR were neither analyzed nor
even acknowledged in this study.
In contrast to the above studies, several clinical
studies have indicated that administration of
normal, physiological levels of androgen to
women receiving estrogen therapy actually
decreases breast cancer risk (reviewed in [59]),
but the mechanism behind this- particularly in
regards to AR signaling- is not clear. Agrawal
and colleagues reported that only in the
absence of estrogen will androgens directly
bind to ERα and stimulate the proliferation of
cancerous cells [115]. Finally, in an excellent,
in-depth review of AR in breast cancer, K. M.
McNamara and colleagues acknowledge that
the role of AR in breast cancer risk and progression depends greatly on the specific disease
subtype and the presence or absence of the
other steroid receptors, such as ERα [123]. The
authors further assert that in the presence of
ERα, AR activation appears to counteract disease progression in most breast cancer subtypes. However, a further complication involves
the ratio of AR to ER, which also appears to
affect progression and efficacy of endocrine
treatment. A clinical analysis of 192 ERα+
breast cancer patients carried out by Richer
and colleagues revealed that a high AR to ERα
ratio correlated positively with increased incidence of tamoxifen failure [122]. Despite all the
confusing and contradictory findings, it does
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appear evident that AR could serve as an
important prognostic indicator as long as AR
isoforms, ERα status and estrogen levels are
also taken into account.
ERα-negative breast cancer
ERβ-positive breast cancer
Although studies have found that both mRNA
and protein levels of ERβ are significantly lower
in breast tumors compared to normal breast
tissue [124, 125], approximately 17% of primary breast cancers are ERα-negative/ERβpositive [126, 127]. In addition, 47-60% of all
ERα-negative tumors have been reported to be
ERβ-positive [42, 126]. Most studies agree that
the presence of ERβ in these tumors is correlated with a positive prognosis, as the absence
of ERβ in ERα-negative patients (ERα-/ERβ-) is
associated with early relapse [111, 128-130].
It has also been reported that as breast tumors
become more malignant, ERβ expression
decreases (reviewed in [131]). However, one
recent study carried out by Chen et al. contradicts these findings [132]. The researchers
found that expression of ERβ actually enhanced
cancer progression by inducing the expression
of IL-8, which is known to play a role in angiogenesis and metastasis [132, 133].
Predictably, most of the aforementioned studies failed to differentiate between the various
isoforms of ERβ, which once again could be
responsible for these conflicting results. The
small handful of studies that actually have analyzed the expression of specific ERβ isoforms
have found that ERβ1, -2/cx, -3, and -5 are
expressed at varying degrees in breast tumors
and breast tumor cell lines [42, 43, 134, 135].
ERβ2/cx (also designated simply as ERβ2) is
the main isoform expressed in the hormonesensitive breast tumor cell line T47D, whereas
ERβ5 is the major isoform in the hormoneinsensitive BT20 breast tumor cell line [134].
Increased expression of both ERβ2/cx and
ERβ5 relative to the full-length isoform ERβ1
appears to correlate with increased breast cancer progression [135], and yet increased
expression of ERβ5 has also been positively
correlated with breast cancer survival [136,
137]. A recent clinical study of 95 patients with
ERα-negative invasive breast carcinomas demonstrated a correlation between prognosis and
the ERβ1 to ERβ2 ratio, associating higher lev-
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els of ERβ2 with tumor relapse [138]. Yet despite their apparent statistical significance, the
differences between ERβ1, ERβ2 and tumor
relapse appeared fairly modest, which could be
due to the relatively modest sample size or to
the researchers’ sole use of immunohistochemistry to detect the individual isoforms.
Though the clinical significance of this particular study is somewhat questionable, an earlier
prostate cancer study carried out by Leung et
al. did reveal a correlation between the increased expression of ERβ2 and ERβ5 and enhanced metastasis and poor prognosis [139].
Clearly more studies are needed to better
understand the prognostic value of the various
ERβ isoforms in breast cancer.
Regardless, the overwhelming consensus that
ERβ is a positive prognostic marker is due
largely to the fact that a significant number of
ERβ+ patients respond well to endocrine therapy, such as tamoxifen. Several clinical studies
have shown that patients who are ERα-negative
or even triple negative (ERα-/PR-/HER2-) but
express high levels of ERβ respond well to
tamoxifen [111, 128, 130], whereas low levels
of ERβ correlate with resistance to tamoxifen
treatment [140, 141]. In addition, other chemotherapeutic agents such as doxorubicin and cisplatin have been found to be more effective on
breast cancer cell lines that express ERβ5
[142]. Aside from drug response, modification
of ERβ has recently been shown to indicate
good prognosis as well. Specifically, a clinical
study led by Valerie Speirs found that breast
cancer patients expressing ERβ phosphorylated at serine 105 had more favorable prognosis [143]. Though the mechanism behind this
finding is unknown, it adds yet another level of
complexity to an already complicated ERβ
narrative.
PR-positive breast cancer
ERα-/PR+ breast cancers only account for about
2-7% of total breast cancer cases [81, 144146], although there is controversy over whether or not such cancers actually exist. While
many studies have supported the claim that
ERα-/PR+ is a distinct class of breast tumors
[81, 94, 144-152], skeptics contend that since
PR is an ER target gene, ER expression is a prerequisite for the expression of PR [153-155].
They maintain that the PR positivity in ERα-
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negative tumors may simply reflect methodological errors in detecting PR and/or ERα,
resulting in either a false-negative ERα result or
a false-positive PR result [153, 154]. In fact, it
is possible that tumors denoted as ERα-/PR+
may actually have fairly low levels of ERα- far
below the sensitivity of the current assays
[153]. Furthermore, results from Iwase et al.
have indicated the possibility that the presence
of ERα variants may exist in ERα-/PR+ tumors,
specifically a variant with a deletion of exon 5
[156]. Though the presence of this variant in
human breast tumors was confirmed in three
other studies [157-159], this and other ERα
variants may be difficult to detect via the traditional ERα assays used in immunohistochemistry, thus complicating the ERα status of certain
mammary tumors. However, ERα aside, the PR
promoter has been shown to be regulated by
other transcription factors such as AP-1 and
SP-1 [160-162]. In fact, an earlier study by
Encarnación et al. indicated that while most of
the ERα+ tumors converted to an ERα- phenotype, the PR status remained unchanged, further supporting the existence of an ERα-/PR+
clinical subtype and the possibility that PR can
be regulated by signaling pathways other than
ERα [163].
Although the expression of PR in breast cancer
cells has been linked to both positive endocrine
response and clinical outcome [82], it is unclear
how PR affects the outcome in ERα-negative
breast cancers. Multiple reports have indicated
that ERα-/PR+ breast tumors constitute a distinct clinicopathological group of cancers that
results in outcomes worse than those that are
ERα+/PR+ or ERα+/PR-, yet results in a better
prognosis than double negative tumors (ERα-/
PR-) [144, 152, 164-166]. It is questionable
whether this clinical subtype of tumor is responsive to endocrine therapies like tamoxifen. As
noted earlier, PR has been shown to be an indicator of responsiveness to endocrine therapy in
the presence of ERα, and thus it is conceivable
that ERα-/PR+ tumors may also respond to
tamoxifen. On the other hand, since current
endocrine therapies are believed to target the
ERα signaling pathway, it seems counterintuitive to attempt such therapeutic options on
ERα-/PR+ cancer patients, particularly since the
presence of PR in ERα+ tissues merely indicates a functional ERα, the presence of which
is believed necessary for tamoxifen to have any
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effect. Yet a recent study by Yang et al. found
that patients with low-grade ERα-/PR+ tumors
did experience an overall survival benefit from
adjuvant hormone therapy using tamoxifen;
and conversely, no benefit was observed in
patients with high-grade ERα-/PR+ tumors [96].
Unfortunately, the scarcity of studies on this
particular clinical subtype limits our ability to do
a complete evaluation of the effectiveness of
tamoxifen.
Theoretically, tumors that are ERα-/PR+ should
be treatable with selective progesterone receptor modulators (SPRM), also referred to as antiprogestins. Anti-progestins such as mifepristone (RU-486) have been proposed as a new
form of endocrine treatment or as an adjunct to
the anti-estrogenic treatments for breast cancer. Multiple in vitro studies using cancer cell
lines have indicated that low doses of anti-progestins can inhibit PR- and estrogen-mediated
cell proliferation [167-169]. Contrary to these
observations, other studies have demonstrated that at higher concentrations, mifepristone
and other anti-progestins can actually stimulate proliferation of the ER+/PR+ breast cancer
cells, T47D and MCF7 [170-172], indicating that
the effect of anti-progestins on proliferation is
dose-dependent and perhaps even dependent
on the level of functional ERα. The few clinical
studies that have tested the effectiveness of
anti-progestins show limited to minimal efficacy
in treating PR+ breast cancer [173-175]. Yet
there is evidence that anti-progestins can augment the effects of anti-estrogens like tamoxifen [176-178]. Clearly, further clinical studies
are necessary to determine if PR is a viable
therapeutic target in ERα- breast cancer.
AR-positive breast cancer
AR has been found in a significant number of
ERα-negative tumors as well, with 22 to 49% of
ERα-negative breast tumors expressing AR,
depending on the clinical study [114, 118, 179,
180]. The presence of AR in ERα- breast cancer
is often associated with lower tumor grade,
smaller tumor size, and significant increase in
survival rates. Results inconsistent with these
clinical data have been reported by some
researchers who have found that androgenenhanced expression of AR in the ER-/PR-/
HER2+ breast cancer cell line MDA-MB-453
increases cell proliferation [181, 182], which
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can be inhibited by the AR antagonist bicalutamide [182]. Additionally, Richer et al. found
that the AR inhibitor enzalutamide inhibited cell
proliferation in ERα-/AR+ breast cancer cell
lines [122]. Given that isoforms of AR were not
taken into consideration in any of these studies, such contradictory findings between clinical and in vitro studies are not that surprising.
A fraction of triple-negative breast cancer
cases (13-35%) appear to express AR [180,
183, 184]. Although some in vitro studies on
triple-negative/AR+ cell lines have demonstrated an androgen-induced increase in cell proliferation [182, 185], most clinical studies find
that the presence of AR in triple-negative
tumors is correlated with a lower recurrence
rate, fewer positive lymph node and distant
metastases, lower histological grade, and higher overall survival rate compared to triple-negative tumors that are AR-negative [180, 183,
184, 186]. These data support the notion that
AR can be used as a positive prognostic factor,
not only in ERα-negative but also triple-negative breast cancers.
In addition to its prospective use as a prognostic biomarker for breast cancer, additional studies have indicated that AR may also serve as a
potential therapeutic target for those breast
cancer patients who traditionally have had very
few treatment options, such as those whose
tumors are ER-/PR-/AR+. Hardin and colleagues
tested the effectiveness of the androgen dehydroepiandrosterone sulfate (DHEAS) on ER-/
PR-/AR+ breast cancer cell lines and found that
DHEAS stimulation of AR hampered cell growth
by enhancing apoptosis [187]. Conflicting studies by Ni et al. and Arce-Salinas et al. showed
that inhibiting AR with the antagonist bicalutamide led to growth inhibition and enhanced
cell death [182, 188]. Interestingly, AR expression seems to be correlated with the overexpression of the oncogene HER2 via a complicated signaling cascade that involves
upregulation of HER2 by AR and transcription
factor β-catenin [182]. In addition, expression
of the constitutively active AR variant AR-V7 in
both ERα- breast cancer cell lines (e.g. MDAMB-453) and ERα- primary tissues is actually
enhanced by the AR antagonist enzalutamide,
which in turn increases cell growth and, as with
more advanced stages of prostate cancer,
could result in ADT resistance [71]. Clearly the
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use of AR as a therapeutic target is wrought
with complications, as both agonists and antagonists of AR have succeeded in either suppressing or promoting tumor progression, and
success appears to be highly dependent on AR
isoform expression and ERα levels.
Discussion and conclusion
Triple negative breast cancer (i.e. ER-/PR-/
HER2-) is virtually impossible to treat with the
established endocrine-based therapies, as
such therapies were originally intended for cancers that are ERα-positive. However, our review
illustrates how confining the triple negative
designation can be, potentially preventing clinicians from considering other factors that play a
role in breast cancer progression. Data
obtained from basic and translational research
studies indicate that there are indeed many
other proteins involved in breast cancer development and progression; but despite these
findings, most clinical pathologists continue to
follow the standard practice of categorizing
breast tumors using only the three established
markers- ERα, PR, and HER2. This apparent
disconnect between the bench and the clinic is
alarming when one considers that 10-15% of
breast cancers are diagnosed as triple negative
[2, 3] and that even patients diagnosed as ERαpositive do not all respond equally well to antiestrogen treatment, which further demonstrates the complexity of breast cancer and
emphasizes the need for more therapeutic
targets.
The goal of this review was to determine if other
steroid hormone receptors- most notably ERβ
and AR- should also be routinely analyzed and
used as additional targets for breast cancer
treatment and prognosis. Although a significant
number of studies exist describing the presence of ERβ, AR, and PR in breast cancer cells
or tissues, obtaining truly accurate expression
levels from the literature proved difficult as all
three of these receptors exist in at least two
isoform states. Most studies did not account
for this variability. Therefore, it is probable that
many isoforms went undetected, which in turn
could have led to an underestimate of a receptor’s actual expression level. Yet, quantitative
inaccuracies aside, we still found very strong
evidence that each of these receptors influences tumor progression, either negatively or posi-
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tively, depending upon which isoforms are present and the level of ERα expression. For
example, ERα+/PR+ breast tumors are generally
found to be more responsive to endocrine treatment than ERα+/PR- tumors [85, 91, 93-96],
and yet a higher expression level of the PR-A
isoform compared to PR-B has been associated with anti-estrogen resistance and subsequently poorer prognosis [102]. The isoforms of
ERβ are capable of forming heterodimers with
ERα, inhibiting ERα activity and consequently
resulting in tumor suppression. However, other
studies have shown a positive correlation
between tumor progression and increased levels of ERβ2/cx and ERβ5 isoforms relative to
ERβ1 [135, 138, 139]. The expression of certain isoforms, such as ERβ5, has also been correlated with positive drug response [142].
Unfortunately, due to the relative scarcity of
studies analyzing AR in breast tumors, few clinically significant associations were found
between a specific AR isoform and breast
tumor progression. However, certain splice variants such as the ligand-independent isoform
AR-V7 have been shown to impact tumor development and progression in prostate cancer
[67, 68], and a recent study by the Tilley lab
strongly suggest that it may have the same
impact on breast cancer progression [71].
Additionally, the available data do show that
the presence of AR is correlated with good
prognosis for both ERα-positive and ERαnegative breast cancer, indicating that antiandrogen therapy might be a viable option in
certain breast cancers as it is in prostate
cancer.
We acknowledge that more basic research is
necessary to elucidate the molecular mechanisms behind the steroid hormone receptors’
effects on breast cancer development and progression. In particular, more studies are needed to better understand how ERβ, PR, and AR
influence cell proliferation, apoptosis, and
metastasis. However, in the interest of saving
lives, we feel that the existing data justify collecting more clinical data on a more massive
scale. We contend that all breast tumor biopsies should be analyzed not only for ERα, HER2,
and overall PR expression but also for each isoform of ERα, PR, ERβ, and AR. Obviously this is
an ambitious undertaking that would require
developing new techniques and improving current detection methods for each isoform. In
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addition, subsequent large-scale analysis of
the data will be necessary to determine if consistent patterns emerge linking the various
expression levels of these markers and their
isoforms with particular grades and stages of
breast cancer.
More and more clinical labs are trending
towards molecular diagnostic procedures such
as next generation sequencing (NGS), RNA
sequencing, and high-throughput qRT-PCR, all
of which will allow scientists to analyze more
genetic markers in a relatively short period of
time. Additionally, the isolation and analysis of
circulating cell-free DNA (ccfDNA) could allow
for initial prognosis using very little sample. In
fact, several clinical and translational studies
have already shown how NGS and ccfDNA analysis can aid in breast cancer prognosis and
tumor classification [189-193]. However, techniques such as NGS are best suited for patients
who may have a genetic predisposition for a
particular cancer (e.g. BRCA1 and BRCA2 in
some familial breast cancers); and though RNA
sequencing and qRT-PCR do give information
regarding transcriptional expression, it is at the
protein level that phenotypes are often
determined.
Therefore, although the utilization of molecular
techniques will enable clinicians to obtain more
information about a patient’s tumor, these
techniques should always be used in conjunction with protein expression analyses- particularly since not all of the steroid receptor isoforms are due to splicing variations but instead
are generated post-translationally. In addition,
post-translational modifications such as phosphorylation and glycosylation cannot be detected at the DNA or RNA level but only by analyzing
the protein expression profiles of tumors.
Finally, the heterogeneity of the cell population
within an individual tumor must be taken into
account when analyzing all the data this new
technology will generate. To date, the most
common procedures for studying protein expression are immunohistochemistry and western blotting. Though immunohistochemistry
provides an important visual of protein expression variations between tissues and even
between cells within the tumor, and western
blotting is a more stringent and exact method
for detecting isoforms of varying molecular
weights, both depend on antibody-binding,

1627

which is an indirect method of protein detection. Recent advances in multiplexed protein
analysis include mass spectrometry immunohistochemistry (MSIHC), in which metal tags of
varying masses are used to label antibodies,
thus allowing for the simultaneous detection of
up to 100 different protein targets [194]. Such
a technique has been used successfully in analyzing various markers such as ERα, PR, and
HER2 in breast tumor samples [195]. Again,
however, such a technique still relies on antibody recognition and binding. Another technique that involves rapid protein isolation and
sequencing on a large-scale would need to be
developed in future to directly identify the various steroid receptor isoforms expressed in a
given tumor. Ultimately, we envision a multipronged approach to breast cancer analysis
that will allow detection of a variety of markers,
including the many isoforms of ERα, ERβ, PR,
and AR, coupled with the pathology of the
tumor. The overall goal would be to provide
each patient with a more personalized and
accurate prognosis and more effective treatment options, and maybe even render obsolete
the term “triple negative breast cancer”.
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